Amgen sues generic drug maker over bone treatments

04-05-2023

Muireann Bolger

Amgen sues generic drug maker over bone treatments

g0d4ather / Shutterstock.com

Lawsuit concerns multibillion-dollar bone-strengthening drugs | Alleged dearth of information provided to patent owner before biologics licence application was approved.


Amgen, Sandoz, biologics, Prolia, Xgeva, bone-strengthening treatments, lawsuit, generic, multibillion-dollar drugs, Novartis, FDA

LSIPR